IP Library Granted Patent US 9,198,960
Granted Patent B2
US 9,198,960 · App. 14/589,608 · Granted Dec 1, 2015

Methods and compositions using listeria for enhancing immunogenicity by prime boost

Inventors: Thomas W. Dubensky, Jr. (Piedmont, CA); Dirk G. Brockstedt (Richmond, CA); Meredith Lai Ling Leong (Oakland, CA); Keith S. Bahjat (Concord, CA)
Assignee: Aduro Biotech, Inc.
A61K39/0011A61K2039/5152A61K2039/522A61K2039/523A61K2039/53A61K2039/545C12N2799/022C12N2799/023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,198,960
App. No.
14/589,608
Granted
Dec 1, 2015
Kind
B2
Abstract

Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.

Claims (5)

1. A method for enhancing an immune response in a mammal to mesothelin, comprising:

administering to the mammal an effective amount of a boost dose of a vaccine comprising an attenuated Listeria that encodes an expressible, immunologically active portion of mesothelin, wherein the mammal previously had been administered an effective amount of a prime dose of an inactivated tumor cell containing a nucleic acid that encodes granulocyte macrophage-colony stimulation factor (GM-CSF).

2. The method of claim 1 , wherein the attenuated Listeria comprises a mutation that inactivates ActA, InlB, or both ActA and InlB.

3. The method of claim 1 , wherein the attenuated Listeria is ΔactAΔinlB.

4. The method of claim 1 , wherein the attenuated Listeria is killed but metabolically active (“KBMA”).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2021
From: CHINOOK THERAPEUTICS, INC.
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 057684/0362 →
CHANGE OF NAME Recorded Oct 1, 2021
From: ADURO BIOTECH, INC.
To: CHINOOK THERAPEUTICS, INC.
Reel/Frame 057684/0448 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2015
From: BAHJAT, KEITH S.
To: ADURO BIOTECH, INC.
Reel/Frame 036615/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2015
From: DUBENSKY, THOMAS W., JR.; BROCKSTEDT, DIRK G; LEONG, MEREDITH LAI LING
To: ADURO BIOTECH, INC.
Reel/Frame 035580/0967 →
Continuity (3)
Continuation 12374288
Provisional Application 60831360 · Jul 17, 2006
Related Publication 20150125485A1 · May 7, 2015